Currently Akt (MK2206) and mTOR (Temsirolimus) inhibitors are being evaluated in clinical trials for patients with various forms of cancer including prostate cancer (NCT01480154, 00919035). The gene discussed is AKT1; the disease is Familial prostate cancer.